DexCom, Inc. provided earnings guidance for the year 2024. For the year, the company expects revenue of approximately $4.20 billion to $4.35 billion (17% - 21% organic growth).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.4 USD | -0.42% | +3.39% | +5.86% |
30/04 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
26/04 | Wall Street: the worst week of 2024 is followed by the best | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.86% | 5.22TCr | |
-5.43% | 18TCr | |
+4.30% | 11TCr | |
-3.09% | 6.83TCr | |
+8.15% | 4.43TCr | |
+6.67% | 4.27TCr | |
+25.54% | 3.25TCr | |
+20.03% | 2.6TCr | |
+1.00% | 2.59TCr | |
-1.25% | 2.47TCr |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- DexCom, Inc. Provides Earnings Guidance for the Year 2024